Skip to Main Content

Paper Details

Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress.
Cell Rep
134
2020
AR, ATR, NE, PARP, PC, PCs, Prostate Cancer, Prostate cancers, RB1, RB1-deficient tumors, TP53, adenocarcinomas, gene, tumor, tumor cells, tumors
Author NameAffiliation
Alexandra CorellaDivisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center
Ilsa ColemanDivisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center
Colin C PritchardUniversity of Washington
Gail P RisbridgerMonash University
Bruce MontgomeryUniversity of Washington
Colm MorrisseyUniversity of Washington
Eva CoreyUniversity of Washington
Peter S NelsonDivisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington
Peter S NelsonDivisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington
  • 1 - 9

Datasets

Release 1.2